soul trial oral semaglutide cardiovascular outcomes 2024 2025 results SOUL: Cuts CV Events in Diabetic Patients soul trial oral semaglutide cardiovascular

Acknowledgements This work was supported by the National Key Research and Development Program of China No

doi:10.36849/JDD.8605

A common starting dose is 0.25mg per week, which then escalates to 0.5mg, 1mg, 1.7mg, and eventually up to a maximum of 2.4mg per week for weight loss in branded versions like Wegovy

Consistently, hepatic expression of LXR target genes, such as Fasn , Scd1 and Acaca , positively correlates with liver steatosis and liver TG in MASLD mouse models, whereas Srebf1 expression positively correlates with plasma TG 40 (Extended Data Fig

After a minute or two, it is degraded by an enzyme known as DPP-4 (dipeptidyl peptidase-4)

Webinar Details Date: Thursday, June 4, 2026 Time: 3:00 pm 4:00 pm ET Registration for this event is now closed